Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 9.66 Billion EUR | -53.79% |
| 2022 | 20.91 Billion EUR | 5.35% |
| 2021 | 19.85 Billion EUR | 6.86% |
| 2020 | 18.58 Billion EUR | -3.15% |
| 2019 | 19.18 Billion EUR | 8.67% |
| 2018 | 17.65 Billion EUR | 10.08% |
| 2017 | 16.03 Billion EUR | -2.3% |
| 2016 | 16.41 Billion EUR | 4.02% |
| 2015 | 15.78 Billion EUR | -1.9% |
| 2014 | 16.08 Billion EUR | 2.75% |
| 2013 | 15.65 Billion EUR | -4.65% |
| 2012 | 16.41 Billion EUR | -1.49% |
| 2011 | 16.66 Billion EUR | 22.75% |
| 2010 | 13.57 Billion EUR | 205.54% |
| 2009 | 4.44 Billion EUR | 23.79% |
| 2008 | 3.59 Billion EUR | -3.87% |
| 2007 | 3.73 Billion EUR | 2.07% |
| 2006 | 3.65 Billion EUR | 6.76% |
| 2005 | 3.42 Billion EUR | 12.16% |
| 2004 | 3.05 Billion EUR | 282.89% |
| 2003 | 798 Million EUR | -3.08% |
| 2002 | 823.36 Million EUR | 2.28% |
| 2001 | 805 Million EUR | 9.23% |
| 2000 | 737 Million EUR | -3.53% |
| 1999 | 764 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 10.6 Billion EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 21.63 Billion EUR | 0.0% |
| 2023 Q4 | 9.66 Billion EUR | 0.0% |
| 2023 FY | 9.66 Billion EUR | -53.79% |
| 2022 Q4 | 20.91 Billion EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 20.91 Billion EUR | 5.35% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 9.36 Billion EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q4 | 19.85 Billion EUR | 0.0% |
| 2021 Q2 | 9.26 Billion EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2021 FY | 19.85 Billion EUR | 6.86% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 18.58 Billion EUR | 0.0% |
| 2020 Q2 | 8.89 Billion EUR | 0.0% |
| 2020 FY | 18.58 Billion EUR | -3.15% |
| 2020 Q3 | - EUR | -100.0% |
| 2019 Q4 | 19.18 Billion EUR | 0.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 Q2 | 8.42 Billion EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 FY | 19.18 Billion EUR | 8.67% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q1 | 7.03 Billion EUR | -56.13% |
| 2018 FY | 17.65 Billion EUR | 10.08% |
| 2018 Q4 | 17.65 Billion EUR | 0.0% |
| 2018 Q2 | 7.36 Billion EUR | 4.66% |
| 2017 FY | 16.03 Billion EUR | -2.3% |
| 2017 Q2 | 7.24 Billion EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 16.03 Billion EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 16.41 Billion EUR | 4.02% |
| 2016 Q4 | 16.41 Billion EUR | 0.0% |
| 2016 Q3 | - EUR | -100.0% |
| 2016 Q2 | 7.06 Billion EUR | 0.0% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 15.78 Billion EUR | -1.9% |
| 2015 Q3 | - EUR | -100.0% |
| 2015 Q2 | 7.14 Billion EUR | 0.0% |
| 2015 Q4 | 15.78 Billion EUR | 0.0% |
| 2014 Q1 | - EUR | -100.0% |
| 2014 Q4 | 16.08 Billion EUR | 0.0% |
| 2014 Q2 | 6.78 Billion EUR | 0.0% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 FY | 16.08 Billion EUR | 2.75% |
| 2013 Q3 | - EUR | -100.0% |
| 2013 Q4 | 15.65 Billion EUR | 0.0% |
| 2013 FY | 15.65 Billion EUR | -4.65% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 6.85 Billion EUR | 0.0% |
| 2012 FY | 16.41 Billion EUR | -1.49% |
| 2012 Q4 | 16.41 Billion EUR | 0.0% |
| 2012 Q2 | 6.58 Billion EUR | 0.0% |
| 2011 Q4 | 6.05 Billion EUR | 0.0% |
| 2011 Q2 | 6.26 Billion EUR | 0.0% |
| 2011 FY | 16.66 Billion EUR | 22.75% |
| 2010 Q2 | 5.11 Billion EUR | 0.0% |
| 2010 Q4 | 5.02 Billion EUR | 0.0% |
| 2010 FY | 13.57 Billion EUR | 205.54% |
| 2009 Q4 | 4.44 Billion EUR | 0.0% |
| 2009 Q2 | 4.27 Billion EUR | 0.0% |
| 2009 FY | 4.44 Billion EUR | 23.79% |
| 2008 Q4 | 3.59 Billion EUR | 0.0% |
| 2008 FY | 3.59 Billion EUR | -3.87% |
| 2008 Q2 | 3.75 Billion EUR | 0.0% |
| 2007 Q4 | 3.73 Billion EUR | 0.0% |
| 2007 FY | 3.73 Billion EUR | 2.07% |
| 2007 Q2 | 3.93 Billion EUR | 0.0% |
| 2006 Q4 | 3.65 Billion EUR | 0.0% |
| 2006 Q2 | 3.6 Billion EUR | 0.0% |
| 2006 FY | 3.65 Billion EUR | 6.76% |
| 2005 Q4 | 3.42 Billion EUR | 0.0% |
| 2005 Q2 | 3.3 Billion EUR | 0.0% |
| 2005 FY | 3.42 Billion EUR | 12.16% |
| 2004 Q4 | 3.05 Billion EUR | 0.0% |
| 2004 FY | 3.05 Billion EUR | 282.89% |
| 2004 Q2 | 842.79 Million EUR | 0.0% |
| 2003 Q2 | 829.13 Million EUR | 0.0% |
| 2003 FY | 798 Million EUR | -3.08% |
| 2003 Q4 | 798 Million EUR | 0.0% |
| 2002 FY | 823.36 Million EUR | 2.28% |
| 2002 Q4 | 823.36 Million EUR | 0.0% |
| 2002 Q2 | 819.37 Million EUR | 0.0% |
| 2001 FY | 805 Million EUR | 9.23% |
| 2000 FY | 737 Million EUR | -3.53% |
| 1999 FY | 764 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AstraZeneca PLC | 5.41 Billion USD | -78.46% |
| Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | -263.11% |
| CSPC Pharmaceutical Group Limited | 442.43 Million USD | -2084.745% |
| Clarus Therapeutics Holdings, Inc. | 14.21 Million USD | -67903.377% |
| Novartis AG | 5.91 Billion USD | -63.47% |
| PT Kalbe Farma Tbk. | 451.27 Million USD | -2041.908% |